Swiss Biotech Day: Basel based BioVersys successfully completed an approximately CHF 80 million IPO in February to advance its work in antimicrobial resistance
May 6, 2025
10:32
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Co-Founder & CEO Marc Gitzinger describes the success factors behind the IPO and walks us through the company's two lead programs. Plus, his thoughts on the evolving business model for this field.